Skip to main content
S&P 5007,605.41+0.26%DOW52,031.40-0.12%NASDAQ26,149.03+0.64%BTC$75,705.00-0.76%ETH$2,389.42-1.19%GOLD$4,387.70+1.27%OIL$102.69-2.97%
Smart Investors Daily
FT

NASDAQ · FTRE

Fortrea Holdings Inc.

Healthcare · Biotechnology

$19.73

Up+$0.41 (+2.07%)

Updated Sep 16, 2026, 4:31 PM

SID Score

5.0/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
1.4B
P/E ratio
-1.4
Dividend yield
0.00%
52-week range
$8.31 – $21.39
Volume
1.95M
Avg. volume
1.34M

Price performance

FTRE price history

1M range · 20 trading sessions · Daily adjusted prices

FTRE closed at $19.73 after 20 trading sessions, up 12.10% for the selected period.

Last close
$19.73
Period change
+12.10%
Period low
$16.79
Period high
$19.73
Daily close
View OHLC price history
FTRE OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 15, 2026$17.21$19.915$17.155$19.731.95M
Sep 14, 2026$17.22$17.67$16.98$17.412M
Sep 11, 2026$17.10$17.57$16.84$17.201.43M
Sep 10, 2026$16.36$17.03$16.0717$17.02741.16K
Sep 9, 2026$16.86$17.09$16.70$16.791.24M
Sep 8, 2026$17.28$17.61$16.86$17.061.52M
Sep 4, 2026$18.50$18.50$17.64$17.70762.08K
Sep 3, 2026$18.67$18.99$18.18$18.62776.31K
Sep 2, 2026$17.91$19.00$17.81$18.36902.45K
Sep 1, 2026$18.38$18.51$17.62$17.721.19M
Aug 31, 2026$18.60$18.77$18.02$18.371.51M
Aug 28, 2026$18.765$19.14$18.46$18.811.14M
Aug 27, 2026$18.70$19.34$18.55$18.861.32M
Aug 26, 2026$18.10$18.55$17.99$18.53598.3K
Aug 25, 2026$18.33$18.64$17.87$18.27599.53K
Aug 24, 2026$18.34$18.45$17.78$18.311.05M
Aug 21, 2026$18.23$18.539$17.82$18.39864.12K
Aug 20, 2026$17.88$18.765$17.87$18.191.52M
Aug 19, 2026$17.93$18.49$17.8675$18.141.03M
Aug 18, 2026$17.80$18.10$17.405$17.60682.08K

Latest FTRE news

The latest Smart Investors Daily articles mentioning FTRE.

Stock researchCompany · Overview

FTRE research

Overview

Company profile and research snapshot.

Company profile

Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$13.60
Implied upside
—
Analysts
—
FTRE recent ratings
DateFirmRatingTarget
Aug 4, 2026TD CowenBuy—
Jul 31, 2026CitigroupBuy—
Jul 30, 2026Truist SecuritiesBuy—
Jul 30, 2026Evercore ISI GroupOutperform—
Jul 30, 2026BarclaysEqual-Weight—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 10, 2026

Fortrea Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

DURHAM, N.C., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (“CRO”), today announced the granting of an inducement award of restricted stock units (“RSUs”) and performance share units (“PSUs”) on September 10, 2026, to five newly hired employees. Included in these awards were grants of employment inducement awards to Jason Knoblauch, the Company’s recently appointed Chief Financial Officer, as an inducement material to

Yahoo · Sep 10, 2026

Fortrea to Participate in September Investor Conferences

DURHAM, N.C., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE), a leading global contract research organization (“CRO”), today announced that CEO Anshul Thakral, CFO Jason Knoblauch, and SVP of Investor Relations, Tracy Krumme will participate in the following conferences in September: Baird 2026 Global Healthcare Conference (NYC) Date: Tuesday, September 15, 2026Format: Fireside Chat & 1x1 and Group MeetingsTime: 2:00 -2:30 PM EDTWebcast: FTRE Baird Webcast Deutsche Bank 2026 Healthcar

Benzinga · Sep 10, 2026

Fortrea Reinstates Jason Knoblauch As CFO

David Smith, a current director on the Board, had acted as Interim Chief Financial Officer and principal financial officer during Mr. Knoblauch’s leave of absence. In connection with Mr. Knoblauch’s reinstatement, Mr.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By